Effectiveness of Laying-on-of-hands for Sickle Cell Disease

NCT ID: NCT01518218

Last Updated: 2015-04-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-03-31

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to evaluate the effectiveness of 1-year administration of laying-on-of-hands on the morbidity and mortality of patients with sickle cell disease in Africa.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with sickle cell disease (SCD) have a high risk of premature death in Africa, mainly due to insufficient medical services. SCD patients often visit emergency department and need hospitalization when they suffer from severe pain; however, they manage most of painful episodes at home. Appropriate pain management at home is, therefore, crucial to improve their clinical course and quality of life. Laying-on-of-hands may be a good candidate for home care management, because family member(s) can become a practitioner of laying-on-of-hands without difficulty and administer it to their loved one as an initial treatment whenever necessary. There are no reports concerning the effectiveness of laying-on-of-hands for the outcomes of SCD patients, as far as we have investigated.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sickle Cell Disease Pain Crisis Recurrent Anemia Infection Death

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

laying-on-of-hands

Patients of this arm received laying-on-of-hands twice a day (45 minutes each) every weekday for 1year, and received conventional medical treatment if necessary.

Group Type EXPERIMENTAL

laying-on-of-hands

Intervention Type BEHAVIORAL

The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.

control group

Patients of this arm did not receive any alternatives other than conventional treatment.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

laying-on-of-hands

The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Okada Purifying Therapy biofield therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients with symptoms associated with sickle cell disease
* those able to receive laying-on-of-hands every weekday for 1 year
* those able to receive conventional medical treatment whenever necessary
* those able to receive blood test at the beginning, after 6 month and after 1 year

Exclusion Criteria

* those who wish to use other complementary and alternative therapies along with laying-on-of-hands
Minimum Eligible Age

3 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

MOA Health Science Foundation

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kiyoshi Suzuki

president

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Kodondi K Koto, MD, PhD

Role: STUDY_DIRECTOR

The Institute of Scientific Research for Health, Kinshasa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The national medical center for sickle cell disease

Kinshasa, , Democratic Republic of the Congo

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Democratic Republic of the Congo

References

Explore related publications, articles, or registry entries linked to this study.

Minga TM, Koto FK, Egboki H, Suzuki K. Effectiveness of biofield therapy for individuals with sickle cell disease in Africa. Altern Ther Health Med. 2014 Jan-Feb;20(1):20-6.

Reference Type DERIVED
PMID: 24445353 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.moainternational.or.jp

MOA International Corporation

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MOA-002

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.